Record Revenue Masks Greenfield Headwinds
Manipal hit ₹3,399 Cr in Q2 revenue, +37% YoY on pure volume growth. But the PAT story is muddier: management conflated H1 profit with Q2 in the opening remarks, and ₹13 Cr in greenfield losses are eating into the upsurge. The quarter reveals a company entering its capex cycle, not a breakout.
₹285 Cr
8.1% margin, +17.1% QoQ
₹639 Cr
10% margin — but this was H1, not Q2
₹13 Cr
Electronic City greenfield loss; capex cycle tax
The PAT muddle
In opening remarks, management stated ₹639 Cr PAT at 10% margin. The delivered Q2 result is ₹285 Cr PAT at 8.1% margin. The ₹639 Cr figure is H1 FY27 profit, not Q2 alone. This framing choice—leading with an H1 number as if it were the quarter—muddied clarity on what the business actually earned in Q2. It's the kind of slip that trips analysts, and it happened on a call where profit growth had already turned cautious.
Opening remarks statement cited ₹639 Cr PAT (10% margin); Q2 delivered ₹285 Cr (8.1% margin). The 4.1 pp margin gap reflects integration and greenfield ramp costs not fully called out until later in the call.
What actually drove the quarter
Strip away the confusion and the quarter is clear: revenue hit a record ₹3,399 Cr, up 37% YoY and 10% QoQ. Volume did the work. Inpatient admissions rose 35% YoY, outpatient 27% YoY. Occupancy climbed to 70% (from 65% QoQ), average revenue per occupied bed (ARPOB) sat at ₹70.6k per day, +8% YoY. This is textbook operational execution—a high-occupancy, volume-led quarter in a growing market.
The profit, though, tells a different story. PAT grew 17.1% QoQ, but that's slower than the 37% revenue growth. Why the gap? Two culprits. First, Electronic City, the greenfield in Bangalore, posted an ₹13 Cr EBITDA loss in Q2 as it ramps clinical capabilities and physician staffing. Second, the broader capex cycle is now underway—₹2,000 Cr budgeted for FY27, ₹4,000 Cr over the next 3–4 years—and the interest and depreciation drag is starting to show in the PAT line.
Q2 revenue ₹3,400 Cr, 37% YoY growth
₹3,399.3 Cr delivered; YoY % aligns with narrative
Supported
Q2 EBITDA ₹882 Cr at 26% margin incl. Sahyadri
₹882 / ₹3,399.3 = 25.9% ≈ 26%
Supported
Q2 PAT ₹639 Cr, 10% margin
Q2 actual ₹285 Cr (8.1%); ₹639 Cr is H1 total
Overstated / Conflated
Volume-led: inpatient +35%, outpatient +27% YoY
Occupancy 70% (+5 pp QoQ), 2.8-day LOS (industry-leading), ARPOB ₹70.6k/day (+8% YoY)
Supported
Sahyadri Q2 EBITDA ₹73 Cr, 19.5% margin
Greenfields Kanakapura & Yelahanka at 24–25% <1 yr; trajectory ahead of 4–5 yr target
Supported and impressive
What changed on this call
Three things shifted from the prior quarter's narrative.
Greenfield timeline extended: Electronic City ramp is slower than initially flagged. ₹13 Cr EBITDA loss in Q2 signals multi-quarter path to breakeven, not the near-term inflection management had implied. Gurugram is now a 3–4 yr build, not a near-term catalyst.
Digital revenue breaking through: At 23% of H1 revenue (e-pharmacy 34k orders/qtr, telehealth 38k consultations, Manipal AI chatbot 24k interactions), digital is maturing faster than peer benchmarks and creating a non-capex revenue stream.
Sahyadri margin inflection ahead of plan: Greenfields Kanakapura and Yelahanka already at 24–25% EBITDA margin <1 yr post-launch, beating the 23–24% target that was supposed to take 4–5 years. The acquisition thesis is playing out faster.
Occupancy and volume inflection now visible: Occupancy 70% (+5 pp QoQ), industry-leading 2.8-day LOS, ARPOB ₹70.6k/day (+8% YoY). The network is tightening operationally, not just expanding bed count.
The bull-bear ledger
Volume inflection confirmed: +35% inpatient, +27% outpatient YoY; occupancy at 70% with room to spare in existing network
Digital momentum: 23% of H1 revenue, growing faster than capex model can absorb; e-pharmacy, telehealth, AI-chatbot all scaling
Sahyadri margin ramp ahead of curve: 19.5% Q2 vs 15.5% FY26; greenfields already at 24–25% <1 yr, validation of acquisition thesis
Capex cycle beginning but manageable: ₹2,000 Cr FY27 is disciplined; debt repaid ₹500 Cr Q2 (benefit starts H2); interest cost tailwind imminent
Greenfield execution lag: Electronic City ₹13 Cr EBITDA loss; Gurugram, Kinder still ramping. Margin upside delayed 1–2 yr vs early guidance. ROI visibility weak until breakeven.
Government scheme volatility: East India Swasthya Sathi reduction cited; Govt. business 13–14% of mix creates quarterly earnings whipsaw. Scheme policy changes are outside management control.
PAT growth lagging revenue: +37% revenue, +17.1% QoQ PAT. Capex depreciation, integration costs, greenfield losses eating margin gains. Profit growth will lag for 2–3 yr of the build cycle.
Occupancy/clinician scarcity in Tier 2/3: New metros (Mumbai, Raipur, Gurugram) won't replicate Bangalore's 70% occupancy quickly. Clinician talent constraints are real.
Ranked risks: what should concern a holder
Greenfield execution lag (Electronic City ₹13 Cr Q2 loss; Gurugram 3–4 yr timeline)
Medium-HighROI on ₹2,000–₹4,000 Cr capex is delayed. If Electronic City, Gurugram, Kinder each take 2+ yr to breakeven vs 1 yr implied, aggregate PAT accretion is pushed 2–3 yr out. Capex cycle tax extends.
Government scheme volatility (East India Swasthya Sathi cut; 13–14% of mix)
MediumPolicy-driven payer mix shifts create quarterly noise. Scheme instability in East India (Dhakuria, other hubs) can swing occupancy & ARPOB by 2–3 pp, rippling ₹50–₹80 Cr to EBITDA. No visibility on scheme timing.
PAT quality / capex depreciation drag
MediumEBITDA growing at 30% YoY, PAT at <20%. Depreciation on ₹4,000 Cr capex (3–4 yr) will suppress reported profit even as operational EBITDA accelerates. Investors expect PAT to follow EBITDA—it may not for 2+ yr.
Sahyadri insurance rate renegotiation (legal entity unchanged; rebranding pending)
Low-MediumSahyadri Hospitals Private Limited entity status hasn't changed post-acquisition. Insurance rates may not improve as aggressively as hoped. Pune market competitive; already at 19.5%, so upside limited in near term.
Clinician scarcity in Tier 2/3 cities (Mumbai, Raipur, Gurugram)
Low-MediumBangalore densification (14–15 hospitals, 70% occupancy) won't replicate in new metros. Clinician talent gaps will keep occupancy at 50–60% longer than plan, delaying greenfield breakeven.
How the street is positioned
Price and trend: At ₹691.25 (as of today, 2026-11-16), the stock is trading above its SMA20 (₹651.15) and SMA50 (₹686), in a bullish short-term trend. But it's 15% below its all-time high of ₹814, reflecting early-cycle caution. The 52-week range is ₹597–₹814; current price sits +15.8% off the low and -15.1% from the high. RSI at 57.7 signals neutral momentum—room to run in either direction. Volume is increasing, which can precede a fresh move.
Flows and ownership: FII are light at 3.50%, DII stable at 7.18%, and promoters dominant at 72.08%. The low FII suggests foreign money hasn't rushed in on the growth story yet—possibly waiting for greenfield execution proof or profit inflection. A recent block deal (Oct 21) saw GM buy 18.98 lakh shares at ₹630 from PRAZIM TRADING, a non-promoter entity. The ₹630 price was 8% below current levels, suggesting a strategic investor entered on weakness; the spread suggests confidence in a rebound.
The street's reading: The bullish trend and volume increase suggest consensus is betting on the volume inflection and digital momentum to drive a re-rating despite capex headwinds. But the 15% drawdown from ATH and low FII ownership hint at patience—the market is waiting for greenfield execution proof and margin inflection before committing fresh capital. The PAT muddle in the opening remarks likely reinforced that caution; a cleaner next-quarter narrative could unlock re-rating upside.
The debate
What to watch next
1 · Electronic City EBITDA trajectory (H1 FY28)
The ₹13 Cr Q2 loss must narrow materially. Management claims multi-pronged approach (clinical complexity, high-end programs, physician onboarding). If H1 FY28 shows loss halving to ₹5–₹7 Cr, the ramp narrative holds. If losses persist or widen, execution risk is real and breakeven timeline extends.
2 · Gurugram Phase 1 launch & occupancy (H2 FY27 start)
The ₹4,000 Cr capex story hinges on Gurugram. Management guided 3–4 yr for 500 beds. First beds coming online now. Watch for: (a) occupied beds % post-launch, (b) ARPOB trajectory, (c) path to 60%+ occupancy in Y1. A slow ramp here signals clinician/market-building challenges in Tier 1 metros outside Bangalore.
3 · Digital revenue mix & profitability (FY28 H1)
Digital at 23% of H1 revenue is a bright spot, but the call didn't detail profitability (margin, gross profit %). If e-pharmacy, telehealth, AI scale to 25–30% of H1 revenue by FY28 and carry 30%+ margin, this becomes a material PAT accretion source independent of capex cycles. If digital growth stalls or margins compress, it's just a revenue mix shift, not a fundamental lever.
The number to track from here
Adjusted EBITDA (excluding greenfield losses). The quarter delivered ₹882 Cr EBITDA (26% margin). Strip out Electronic City's ₹13 Cr loss and the core business sits at ₹895 Cr (26.3% margin). That's the number to track quarterly: is core EBITDA growing 25–30% YoY while greenfield integration costs remain time-bound (2–3 yr)? If yes, the thesis holds. If core EBITDA stalls and greenfield losses mount, re-rating risk is real.
Manipal delivered a record revenue quarter on the back of genuine volume growth and operational excellence—70% occupancy, +35% inpatient growth, +27% outpatient growth, and a maturing digital franchise at 23% of revenue. But the PAT picture is a steady-state story, not a step-change. Management's opening-remarks confusion (citing H1 PAT as if it were Q2) muddied near-term clarity, and ₹13 Cr in greenfield losses from Electronic City signal that the capex cycle's profit tax is real and will persist 2–3 years.
The stock is not broken. Sahyadri's greenfields are beating the 4–5 yr margin trajectory, digital is scaling, and occupancy inflection is confirmed. But this is a 3–5 yr compounder thesis, not a 1–2 yr re-rating play. Until Gurugram and Electronic City demonstrate margin recovery and greenfield EBITDA reaches cash-generative levels, the business is in capex investment mode—delivering strong EBITDA growth but constrained PAT growth.
For holders: steady execution, not explosive. The stock's 15% drawdown from all-time high is fair valuation for a company entering a capex cycle. For new buyers: wait for H1 FY28 greenfield margin proof, or buy on the thesis that volume inflection + digital upside justify the patience. The key number to track is core EBITDA (₹895 Cr ex-greenfield losses this quarter); if it sustains 25–30% YoY growth over 3 quarters, the 3–5 yr thesis holds, and the ₹691 price becomes a long entry.
Informational and educational content only. Not investment advice.